Chronic thrombo-embolic pulmonary hypertension (CTEPH) is characterized by progressive right ventricular failure and, if left untreated, death. It is preceded by acute pulmonary thrombo-embolism. Unlike other patients with acute pulmonary embolism, however, patients with CTEPH do not lyse the thrombotic material within the pulmonary arteries. Instead, the thrombi are remodeled into intravascular scars that obstruct flow, often with disastrous consequences. Our goal is to understand the mechanisms responsible for the failure to resolve the acute thrombo-emboli in CTEPH. Our previous studies had disclosed no defect within fibrinolytic enzymes in these patients. However, we demonstrated that fibrinogen purified from CTEPH patients is somewhat resistant to lysis by exogenous plasmin. For this reason, we plan to search within the CTEPH patient population for genetic variants of fibrinogen and post-translational modifications which might make it resistant to fibrinolysis. Fibrinogen variants will be searched for in CTEPH patients using three complementary methods. First, purified fibrinogen will be polymerized and cross-linked to simulate normal thrombosis, then exposed to plasmin under controlled conditions to determine the profile of peptide fragments yielded during fibrinolysis, as well as the kinetics of their release. Next, genetic variants in targeted portions of fibrinogen will be looked for using the polymerase chain reaction (PCR) and DMA sequencing. Finally, primary amino acid sequence and post translational modifications will be searched for in fibrinogen from CTEPH, using purified fibrinogen samples fragmented with proteases. The fragments will be subjected to liquid chromatography-mass spectroscopy with data-dependent MS-2 data acquisition, followed by computer-assisted sequence analysis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HL080302-02
Application #
7037448
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Denholm, Elizabeth M
Project Start
2005-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
2
Fiscal Year
2006
Total Cost
$150,746
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Soler, Xavier; Hoh, Carl K; Test, Victor J et al. (2011) Single photon emission computed tomography in chronic thromboembolic pulmonary hypertension. Respirology 16:131-7
Henderson, A Cortney; Prisk, G Kim; Levin, David L et al. (2009) Characterizing pulmonary blood flow distribution measured using arterial spin labeling. NMR Biomed 22:1025-35
Morris, Timothy A; Marsh, James J; Chiles, Peter G et al. (2009) High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 114:1929-36
Morris, Timothy A; Marsh, James J; Chiles, Peter G et al. (2007) Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension. Thromb Res 119:257-9
Morris, Timothy A; Marsh, James J; Chiles, Peter G et al. (2006) Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173:1270-5